Potential Use of Flavopiridol in Treatment of Chronic Diseases.
作者： Thejal Srikumar , Jaya Padmanabhan
DOI: 10.1007/978-3-319-41342-6_9
关键词:
摘要: This chapter describes the potential use of flavopiridol, a CDK inhibitor with anti-inflammatory and anti-proliferative activities, in treatment various chronic diseases. Flavopiridol arrests cell cycle progression G1 or G2 phase by inhibiting kinase activities CDK1, CDK2, CDK4/6, CDK7. Additionally, it binds tightly to CDK9, component P-TEFb complex (CDK9/cyclin T), interferes RNA polymerase II activation associated transcription. turn inhibits expression several pro-survival anti-apoptotic genes, enhances cytotoxicity transformed cells differentiation growth-arrested cells. Recent studies indicate that flavopiridol elicits activity via CDK9 NFκB-dependent signaling. Overall, these effects potentiate its ability overcome aberrant and/or inflammatory stimuli, which are mediators
springer.com
sci-hub.se 参考文章(114)
Sheng-Hao Chao, Koh Fujinaga, Jon E. Marion, Ran Taube, Edward A. Sausville, Adrian M. Senderowicz, B. Matija Peterlin, David H. Price, Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. Journal of Biological Chemistry. ,vol. 275, pp. 28345- 28348 ,(2000) , 10.1074/JBC.C000446200
John C. Byrd, Charlotte Shinn, Jamie K. Waselenko, Ephraim J. Fuchs, Teresa A. Lehman, Phuong L. Nguyen, Ian W. Flinn, Louis F. Diehl, Edward Sausville, Michael R. Grever, Flavopiridol Induces Apoptosis in Chronic Lymphocytic Leukemia Cells Via Activation of Caspase-3 Without Evidence of bcl-2 Modulation or Dependence on Functional p53 Blood. ,vol. 92, pp. 3804- 3816 ,(1998) , 10.1182/BLOOD.V92.10.3804
Jun GUO, An-wu ZHOU, Yu-cai FU, Udit N VERMA, Debu TRIPATHY, Eugene PFRENKEL, Carlos R BECERRA, Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil Acta Pharmacologica Sinica. ,vol. 27, pp. 1375- 1381 ,(2006) , 10.1111/J.1745-7254.2006.00421.X
Elizabeth W. Newcomb, M. Aktar Ali, Tona Schnee, Li Lan, Yevgeniy Lukyanov, Mary Fowkes, Douglas C. Miller, David Zagzag, Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1α expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy Neuro-oncology. ,vol. 7, pp. 225- 235 ,(2005) , 10.1215/S1152851704000997
Anne Pumfery, Cynthia Fuente, Reem Berro, Sergei Nekhai, Fatah Kashanchi, Sheng-Hao Chao, Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Current Pharmaceutical Design. ,vol. 12, pp. 1949- 1961 ,(2006) , 10.2174/138161206777442083
Carolina Alquézar, Estíbaliz Barrio, Noemí Esteras, Ana de la Encarnación, Fernando Bartolomé, José A. Molina, Ángeles Martín-Requero, Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease. Journal of Neurochemistry. ,vol. 133, pp. 886- 897 ,(2015) , 10.1111/JNC.13070
David S Park, Erick J Morris, Rod Bremner, Elizabeth Keramaris, Jaya Padmanabhan, Michele Rosenbaum, Michael L Shelanski, Herbert M Geller, Lloyd A Greene, None, Involvement of Retinoblastoma Family Members and E2F/DP Complexes in the Death of Neurons Evoked by DNA Damage The Journal of Neuroscience. ,vol. 20, pp. 3104- 3114 ,(2000) , 10.1523/JNEUROSCI.20-09-03104.2000
Jason J. Luke, David R. D'Adamo, Mark A. Dickson, Mary Louise Keohan, Richard D. Carvajal, Robert G. Maki, Elisa de Stanchina, Elgilda Musi, Samuel Singer, Gary K. Schwartz, The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial Clinical Cancer Research. ,vol. 18, pp. 2638- 2647 ,(2012) , 10.1158/1078-0432.CCR-11-3203
Deborah M. Stephens, Amy S. Ruppert, Kami Maddocks, Leslie Andritsos, Robert Baiocchi, Jeffrey Jones, Amy J. Johnson, Lisa L. Smith, Yuan Zhao, Yonghua Ling, Junan Li, Mitch A. Phelps, Michael R. Grever, John C. Byrd, Joseph M. Flynn, Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia Leukemia Research. ,vol. 37, pp. 1195- 1199 ,(2013) , 10.1016/J.LEUKRES.2013.06.006
A. M. Senderowicz, Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators Journal of the National Cancer Institute. ,vol. 92, pp. 376- 387 ,(2000) , 10.1093/JNCI/92.5.376